Other
Crozer-Keystone Health System
Total Trials
5
Recruiting
0
Active
2
Completed
2
Success Rate
100.0%+13% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
Failure Rate
0.0%
0 terminated/withdrawn out of 5 trials
Success Rate
100.0%
+13.5% vs industry average
Late-Stage Pipeline
40%
2 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
N/A
1(25.0%)
Phase 4
1(25.0%)
Phase 3
1(25.0%)
Phase 2
1(25.0%)
4Total
N/A(1)
Phase 4(1)
Phase 3(1)
Phase 2(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (5)
Showing 5 of 5 trials
NCT04467983Phase 4Active Not Recruiting
Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone
Role: collaborator
NCT03822494Not ApplicableActive Not Recruiting
CyberKnife Dose Escalation Prostate Cancer Trial
Role: lead
NCT03825510Phase 2Completed
Immunotherapy SBRT Sensitization of the Programmed Death-1 (PD-1) Effect
Role: lead
NCT04517682Completed
COVID-19 and SARS-CoV-2 Detection in Saliva
Role: collaborator
NCT03734471Phase 3Unknown
Reactor Thoracostomy
Role: lead
All 5 trials loaded